Abstract: This paper presents a summary of previous and current research at the Christchurch Hospital Intensive Care Unit from the point of view of an intensive care specialist who has worked in the field for the past 18 years. All the major areas of sedation-agitation, cardiovascular and mechanical ventilation management, glucose control and sepsis diagnosis are covered as case studies, including model developments and clinical outcomes. The overall approach is described as "Model-based Therapeutics" and has the philosophy of a "one method fits all" rather than the more typical "one size fits all" approach. The research presented shows the way forward to next generation health care, where current medical equipment, sensors and drugs are used in a smarter way to develop patient-specific diagnosis and therapy.
INTRODUCTION
Intensive care is one of the most challenging areas of modern medicine. With aging populations and increased complexity of care, the social and economic burden of intensive care is increasing, and accounts for 10%, or more, of all healthcare costs, or 1-1.5% of GDP in western countries. Economically, these costs are beginning to bring some healthcare systems to their knees.
It is also a technology laden area of medicine, with mechanical ventilators, semi-automated infusion pumps, and a wide range of sensors. However, while the technology used continues to evolve and improve incrementally, it has not changed radically in 30 years. Thus, improving patient outcomes, while restraining cost, in the intensive care unit (ICU) of the next 10 years, will revolve around how we use that technology and maximize its potential Importantly, the technology and how clinical staff interpret the information it provides, have not improved patient outcomes or productivity in care while the main cost of intensive care is in clinical staff. Thus, while technology, particularly computers, has driven productivity revolutions in many industries, including parts of medicine, it has failed to do so in the ICU. This paper examines the means by which this issue can be addressed, and how there is a need to develop technologies that overcome these obstacles.
In a typical intensive care there is very little time to diagnose a patient's condition and determine the proper treatment. Patient's lives ultimately can depend on clinical staff doing the right thing at the right time. In addition, while patients are continually monitored, they are only infrequently examined or diagnosed, and at set points in time. Thus, a great deal of potentially valuable information is lost, and the variability that defines the critically ill patient can wreak extensive havoc. What is needed is the ability to accurately and continuously inform bedside clinical staff of what is really going on with their patient -something that modern technologies and physiological knowledge can do in combination. Thus, it's an area which creative and adaptive solutions using engineering and computational methods, mixed with clinical and physiological knowledge, can save lives, time and cost.
The Department of Intensive Care in Christchurch, New Zealand has seen the development of highly innovative health care initiatives including glucose control, cardiovascular and ventilation management, agitation sensing and optimal sedation and real-time sepsis diagnostics (Blakemore et al 2008 , Lonergan 2006a , Lonergan 2006b , Hann et al 2005a ,Smith et al 2004 , Hann et al 2005b , Shaw et al 2003 , Becouze et al 2007 . The glucose control protocol developed has lead to a clinical practice change with significant savings on mortality, cost and overall patient outcome .
The overall approach is referred to as model-based therapeutics or MBT , Lonergan 2006a , Lonergan 2006b . The philosophy is to develop a "one-method-fits all" rather than static or fixed 'one-size-fits all' approaches that predominate in results in randomised clinical trials (RCTs). RCTs produce outcomes of risk based on treatments given. Thus, when this evidence is translated into clinical practice, patients can only be treated for the risk of a particular disease or condition. The result: treatments are given blindly for an indefinite period of time for diseases or conditions that often don't exist. Thus, the "evidence" gained from RCTs can not be used to predict outcomes of treatments titrated to patient-specific responses.
The goal of MBT is to develop patient-specific diagnoses and therapies that make more effective use of existing sensors and technologies.
The common approach in intensive care to patient management is to 'cover all bases' which typically leads to over prescribing of therapies. For example, patients tend to be over-feed, over-sedated, kept on mechanical ventilation for too long, and given far more drugs (e.g. antibiotics and inotropes) than is necessary. Hence, significant costs can be incurred without benefitting patients (Mullner et al 2004) .
The primary problem is that the measurements and patient responses to various therapies given are very complex, even for highly trained specialists, who have to make a best "guess" at what is going on. Hence, this process is often 'hit and miss' and takes time (and error) to get right. For sicker patients who are less tolerant of incorrect treatments, there may be little time to make a correct diagnosis. It is often impossible to know, exactly, the real causes of the particular physiological dysfunction. For example there can be several different conditions affecting the circulation that look the same on the intensive care monitors.
Doctors are helped by using other diagnostic tools, such as cardiac echocardiography, lab tests and computerized tomography (CT) scans. However, these measurements are not available immediately at the bedside, and they require expert technical skills and interpretation, and thus add cost. Finally, no intermittent diagnostic test can truly tell the nurse or doctor what is going on physiologically as it happens (in real-time).
What is required are methods to turn a range of numbers and sensor outcomes into a clear and well-understood physiological picture of patient condition. This approach takes best advantage of the available technology to translate physiological and clinical knowledge in textbooks and research, directly to the bedside in a way that thus best matches clinical training and knowledge. From this outcome, we can create improved productivity in care.
CASE STUDIES

Agitation/sedation:
Sedative delivery in intensive care is fundamental to effective agitation management and is the basis for providing comfort and relief to the critically ill. The yearly cost in the US of sedatives and analgesics in the ICU was estimated to be $0.8-1.2B US in 2001 (Fraser and Riker, 2001) .
A landmark study (Kress et al, 2000) of sedation interruption showed significant reductions in the time spent on mechanical ventilation and the length of stay. Another study (Girard et al, 2008) has shown that sedative interruption in combination with successful spontaneous breathing trials resulted in earlier discharges and increased 12 month survival.
A recent review concludes that systematic interventions to improve sedation practice and maintain patients at an optimal sedation level in the ICU may improve patient outcomes and optimize resource usage (Jackson, et al 2010) . However, when sedation is switched off when patients are not ready to be removed from mechanical ventilatory support, this resulted in an mortality de Wit et al, 2008 . This demonstrates the dangers of simply reducing sedation in a simple protocol without proper knowledge of the underlying dynamics. In other words, it's not what drug or what dose that's given, it's how it's delivered.
Specifically, an objective, physiologically-based, agitation scale, models or understanding of agitation-sedation dynamics, and effective, well-understood infusion protocols are needed Prior research has developed and clinically validated an agitation index with further refinements to include detection of grimacing and quantification (Becouze et al 2007) . Agitation-Sedation Dynamic models have also been developed based on clinical data and have shown significant potential for the development of improved protocols (Rudge, et al 2005) . This approach allows patient-specific drug delivery and should be the focus of new research.
Model-based cardiac diagnosis and therapy:
The approach to cardiovascular management in critical care commonly involves titrating drugs and giving fluids based mainly on arterial pressure but with some other measurements including central venous pressure, ECG and SPO 2 waveforms. The interpretation of this diverse and rather limited data set is very difficult and thus clinical staff primarily rely on experience and intuition to make a diagnosis or administer a treatment. These results cover many common diagnostic difficulties and therapeutic interactions. They are also have unique capabilities. Importantly, the ability to clearly define, in a physiological sense, these issues can dramatically improve diagnosis, therapy selection and care in intensive care. In particular, because cardiovascular dysfunction is a leading cause of ICU mortality, these tools can have immediate impact.
Management of Mechanical Ventilation (MV):
Acute Respiratory Dysfunction Syndrome (ARDS) is a major cause of hospitalization with mortality rates from 30-70% Bersten et al (2002) . Despite many recent studies on MV treatment there are no well established methods to determine an optimal, patient-specific positive end expiratory pressure (PEEP), a critical MV setting, or any other ventilator settings. The objective of this research is to develop a simple model that can be run at the bedside with minimal intervention to optimise PEEP and MV therapy.
Clinical trials are currently in progress, to validate the model's ability to predict the outcome of a change in PEEP on the recruitment of lung units or alveoli. Further, as seen in Figure 2 , the model can assess the impact of PEEP on net recruitment , which is a primary physiological and clinical end-point or goal.
MV is used to improve recruitment of lung units to aid recovery, while minimising excessive tidal volumes and/or pressures that can lead to ventilator induced lung injury (VILI) of healthy units. Hence, the goal is to use PEEP to prevent derecruitment of lung units at end expiration (preventing their collapse and associated damage due to continued recruitment and derecruitment). Hence, the ability to noninvasively capture net recruitment at any PEEP without the need for other technologies, and to do so at any time, will provide significant insight to clinical management of MV. It is clear that a PEEP of 20cmH 2 O is the point at which net recruitment is maximised and thus an optimal, physiologically and clinically relevant PEEP value. Importantly, the initial clinical setting for this trial was a PEEP of 10cmH 2 O, a much lower value that had not been changed in some time, while the patient condition had evolved, illustrating a further advantage in that such a patient-specific, model-based method can be used frequently to evaluate and track patient condition. It is clear from Figure 3 that one would clinically never add PEEP past a point where net increase in recruitment did not change, as it risks VILI, as well as depressing venous return and cardiac output for no gain (or potential loss) in lung function through increased dead space. Thus, the model can provide clear, physiologically and clinically relevant insight that is currently completely blind to the clinical staff managing MV.
Glucose control and sepsis diagnosis
Hyperglycemia is prevalent in critical care, and leads to increased risk of myocardial infarction, organ failure, infection and death. The hyperglycemic critically ill patient is also highly dynamic, with excessive, highly variable insulin resistance due to their condition. Tight glycemic control (TGC) can reduce mortality if blood glucose can be kept in a target range consistently.
Several studies have reduced mortality up to 40% in patients who stay 3-5 days or longer in the ICU , Van den Berghe et al 2006 , Krinsley 2004 ). However, several other studies have failed to replicate these results (NICE-SUGAR study 2009). The difficulty of providing real-time, adaptive and patient-specific TGC that is effective has prevented this therapy from being widely used.
In particular, most protocols are fixed and static, focusing on insulin dosing in response to blood glucose levels . These protocols thus completely fail to address patient-specific and time varying insulin resistance. Thus, what works well for some patients can fail completely for others. This difficulty is a perfect example of the difference between one size fits all, static approaches to care, and the need for adaptive patient specific therapy.
The Christchurch ICU currently uses a model-derived, adaptive and patient-specific system called SPRINT that has reduced mortality 20-40% for patients staying 3-5 days or longer . The system was derived from metabolic system models validated in a wide range of clinical studies in this ICU, and designed specifically for TGC . It thus directly titrates not off blood glucose level but off patient-specific insulin sensitivity, as derived from the nutrition and insulin interventions and resulting blood glucose response.
Equally importantly, the control has been tight enough to significantly reduce sepsis and infection. In addition, recent studies have shown that it significantly reduced the number, severity and rate of organ failure in patients using SPRINT versus a retrospective, matched cohort, indicating that this reduction provided the foundation for improved mortality. Finally, reduced organ failure resulted in reduced costs, and SPRINT has a net cost savings per patient treated of NZ$1052. Surveys showed that net clinical burden also decreased. Thus, SPRINT provides better outcomes and reduced cost, through a model-derived system, illustrating the power of MBT.
Further improvements, including the use of model-based control are forthcoming to provide further savings and productivity gains. In particular stochastic models of patient variability can be used to provide guaranteed levels of safety from hypoglycaemia . This stochastic targeted (STAR) TGC is currently already in use in the Christchurch Womens Hospital Neonatal ICU (LeCompte et al 2009). These models and systems provide direct physiological picture and assessment of the patient's realtime metabolic status, making the optimisation of insulin therapy clearer, more efficient for staff, and more effective for the patient.
Finally, as a glimpse of the future potential of MBT in ICU, these clear physiological pictures of insulin resistance status can be used in other diagnostics. Specifically, patients with sepsis exhibit significantly reduced and variable insulin sensitivity. Thus, this model-based metric, along with other readily available clinical metrics can be used to provide a real-time diagnosis of sepsis (Blakemore et al 2008) . In particular, where new sepsis develops in critically ill patients, this task can be highly challenging to distinguish other nonseptic causes of inflammation. Hence, the clear physiological picture created of metabolic status can be used to improve other areas of care.
CONCLUSIONS
The Christchurch Department of Intensive Care has developed a unique clinical-engineering collaboration with the Department of Mechanical Engineering at the University of Canterbury. This collaboration is highly multi-disciplinary, and has led to the development of clinically validated models of each individual major physiological system for diagnosis and decision support. Clinical outcomes and significant cost savings have already been achieved, and clinical trials are in progress in every major area of the ICU. Hence, there is significant potential to link all the main diagnostic and therapeutic methods. The vision for the future is a fully unified, model-based therapeutics system which integrates all drug delivery devices and sensors and provides significantly improved health care at no extra measurable added cost.
